### HUTCHINSON CENTER

A LIFE OF SCIENCE

# Introduction

The yeast pheromone response signaling system transmits information about the extracellular pheromone (e.g.  $\alpha$ -factor) concentration to the cell nucleus. Experiments, from Brent's laboratory<sup>1,2</sup> and elsewhere<sup>3</sup>, investigated the system response to pheromone at several "measurement points" in the signaling pathway (colored circles in cartoon). They found:

• The signaling system does not adapt over time, but functions at an essentially constant pace for >4 hours. Dose-response behaviors of the different measurement points are graded, meaning that the responses increase smoothly with increasing pheromone dose.

 Dose-response behaviors of the different measurement points are remarkably aligned. We call this phenomenon DoRA, for Dose-Response Alignment.





DoRA is widely observed in other systems too, likely because it improves information transmission<sup>1</sup>.

What mechanisms enable signaling systems to exhibit DoRA? - this is the topic of this poster

# Negative feedback prediction

Negative feedback is often used in engineered systems to control downstream responses and to improve linearity between input and output. Examples range from steam engine governors to electronics operational amplifiers.



In prior work, several of us<sup>1</sup> discovered a new negative feedback in the yeast pheromone response system, from far downstream to far upstream (Fus3 to Ste5). This was a "smoking gun" for the negative feedback that creates DoRA. We planned to prove its feasibility using modeling.





# Signaling mechanisms that can yield Dose-Response Alignment Steven S. Andrews, Richard C. Yu, Gustavo Pesce, and Roger Brent **Basic Sciences**



**3.** Computationally optimize model parameters to get the best fit between model and experimental dose-responses. Fit errors are quantified with a new "slope-weighted RMS difference" metric.



**4.** See what models can or cannot fit experimental data. The modeling scheme is *not* mechanistically accurate. Its results are meaningful if the model has the same capabilities and constraints as real signaling systems. Both model and reality can exhibit any Hill function, and are essentially limited to Hill functions, which suggests the model is valid.

4. Push-pull mechanisms enable a substantially better fit. Here, the normal arrow activates the downstream node while the low-true arrow deactives it.





<u>parameter</u>	<u>value</u>
$n_{lpha, Receptor}$	1.0
<i>n</i> <sub>Receptor,G-protein</sub>	2.3
<i>n</i> <sub>G-protein,Fus3</sub>	0.3
n <sub>Fus3,PRM1</sub>	6.3



6. The model scheme, with push-pull mechanisms and cooperativity, fit 7 experimental yeast dose-response data sets well using a single set of parameters. An 8th data set did not fit, likely due to other consequences of the mutation.



Push-pull mechanisms may arise in the yeast system from (*i*) parallel and complementary Fus3 and Kss1 pathways, (*ii*) a newly discovered G-protein activation mechanism<sup>5</sup>.



The observed Dose-Response Alignment (DoRA) in the yeast pheromone response signaling system likely does *not* arise from negative feedback. Instead, it likely arises from novel push-pull mechanisms and/or cooperativity. These are biologically plausible.

1.	Yu, P Benja
	impro 456:7
2.	Colm and E
3.	decis Yi, Ki
	yeast USA
4.	Black

### Discussion



Cooperativity may arise from (*i*) multiple phosphorylation in the kinase cascade, (*ii*) allosteric interactions in the Ste5 scaffold and other protein complexes.

# Conclusions

# References

Pesce, Colman-Lerner, Lok, Pincus, Serra, Holl, amin, Gordon, and Brent, "Negative feedback that oves information transmission in yeast signaling" Nature 755-761, 2008.

nan-Lerner, Gordon, Serra, Chin, Resnekov, Endy, Pesce, Brent, "Regulated cell-to-cell variation in a cell-fate sion system" Nature 437, 699-706, 2005.

itano, and Simon, "A quantitative characterization of the heterotrimeric G protein cycle" Proc. Nat. Acad. Sci. 100, 10764-10769, 2003.

and Leff, "Operational models of pharmacological agonism" Proc. R. Soc. Lond. B 220:141-162, 1983. 5. Bush, Colman-Lerner, In preparation, 2012.

Funding: NIH, MITRE.